Testing for microalbuminuria and albuminuria in diabetes should be as important as checking blood pressure

References

• Earley LE, Forland M. Nephrotic syndrome. In: Earley LE, Gottschalk CW, editors. Strauss and Welt's diseases of the kidney. Boston: Little, Brown and Company, 1979: 765–813.
   Google Scholar
• Samuelsson 0. Proteinuria as a prognostic factor during long term hypertensive care. Drugs 1988; 35 Suppl 5: 48–54.
   Google Scholar
• Yudkin J, Forest R, Jackson C. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet 1988; II: 530–3.
   Google Scholar
• Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other athero-sclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27: 2033–9.
   PubMed Web of Science ®Google Scholar
• Ritz E. Albuminuria and vascular damage - the vicious twins. N Engl J Med 2003; 348: 2349–52.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diabetic nephropathy. Diabetes Care 1998; 21 Suppl 1: S50–3.
   Google Scholar
• Ritz E. Nephropathy in type 2 diabetes. J Intern Med 1999; 245: 111–26.
   PubMed Web of Science ®Google Scholar
• Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Internal Med 2003; 254: 45–66.
   Google Scholar
• Remuzzi G, Riggenenti P. Slowing the progression of diabetic nephropathy. N Engl J Med 1993; 329: 1496–7.
   PubMed Web of Science ®Google Scholar
• Parving H, Osterby R, Ritz E. Diabetic nephropathy. In: Brenner BM, Levine S, editors. The kidney. Philadelphia: WB Saunders, 2000: 731–73.
   Google Scholar
• Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Dial Transplant 1982; 21: 730–8.
   Google Scholar
• Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of world-wide dimensions. Am J Kidney Dis 1999; 34: 795–808.
   PubMed Web of Science ®Google Scholar
• Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175–9.
   PubMed Web of Science ®Google Scholar
• Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471–4.
   Google Scholar
• Lewis EJ, Hunsickler LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic ne-phropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–62.
   PubMed Web of Science ®Google Scholar
• Lewis El, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–86.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
   Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977–86.
   PubMed Web of Science ®Google Scholar
• Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987; 294: 1443–7.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular com-plications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703–13.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086–97.
   PubMed Web of Science ®Google Scholar
• Aurell M. Aspects of the role of intraglomerular pressure as a cause of progressive renal damage. Drugs 1988; 35 Suppl 5: 42–7.
   PubMed Web of Science ®Google Scholar
• Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36: 449–67.
   PubMed Web of Science ®Google Scholar
• Leehey DJ, Singh AK, Alavi N, Singh R. Role of angio-tensin II in diabetic nephropathy. Kidney Int 2000; 58 Suppl 77: 93–8.
   Web of Science ®Google Scholar
• Burton C, Harris KPG. The role of proteinuria in the pro-gression of chronic renal failure. Am J Kidney Dis 1996; 27: 765–75.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309–20.
   PubMed Web of Science ®Google Scholar
• Mogensen CE. Microalbuminuria predicts clinical protei-nuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356–60.
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen 0. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383–93.
   Google Scholar
• American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25 Suppl 1: 585–9.
   Google Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53. nephropathy.
   Google Scholar
• Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin—angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens 2004; 13: 319–24.
   Google Scholar
• Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646–61.
   PubMed Web of Science ®Google Scholar